Given promising first-in-human results that were recently described for imaging of reactive astrogliosis in AD [17, 18], we sought to target astrogliosis in-vivo in a transgenic mouse model of AD at various ages by means of [18F]F-DED and to provide histological validation using GFAP immunostaining. The gene discussed is GFAP; the disease is Alzheimer disease.